Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717
Recruiting
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: GSK Investigational Site, Philadelphia, Pennsylvania
Conditions: Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Register for Updates
Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation
NCT05721261
Recruiting
A novel temporary peripheral nerve stimulation system that delivers a single dose of electrical stimulation therapy for 1 hour will be evaluated for safety and effectiveness.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2025
Locations: WellSpan Health, York, Pennsylvania
Conditions: Nerve Injury
Register for Updates
Neuro-affective Response to Light in Depressed Adolescents and Young Adults
NCT05712772
Recruiting
The goal of this neuroimaging pilot study is to understand developmental differences in the impact of therapeutic wavelength light (blue light) versus a non-therapeutic wavelength (red light) on emotional brain function in depression. The main questions this study aims to answer are: * Does acute exposure to blue light (vs red light) stabilize emotional brain function in depressed individuals? * Are stabilizing effects of blue light (vs red light) stronger for blue light in adolescents than you... Read More
Gender:
ALL
Ages:
Between 12 years and 30 years
Trial Updated:
08/05/2025
Locations: Western Psychiatric Hospital, Pittsburgh, Pennsylvania
Conditions: Depression in Adolescence, Depression in Adults
Register for Updates
Galleri® in the Medicare Population.
NCT05673018
Recruiting
This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek to enroll approximately 20% of the study participants from under-represented minority populations (e.g., racial / ethnic minority groups, socioeconomically disadvantaged populations, rural populations).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/05/2025
Locations: Geisinger Bloomsburg Hospital, Bloomsburg, Pennsylvania
Conditions: Cancer
Register for Updates
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
NCT05639556
Recruiting
The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies inclu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Cystic Fibrosis
Register for Updates
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059
Recruiting
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/05/2025
Locations: Temple University Hospital, Philadelphia, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728
Recruiting
A Dose Finding Study of \[177Lu\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/05/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Glioblastoma
Register for Updates
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
NCT04903080
Recruiting
This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependymoma that has come back after treatment (recurrent) or has not responded well to treatment (progressive) in children. The HER2 CAR T cells used in this trial are made from the patient's own blood. A new gene, called the H... Read More
Gender:
ALL
Ages:
Between 1 year and 22 years
Trial Updated:
08/05/2025
Locations: Pittsburgh Children's Hospital of UPMC, Pittsburgh, Pennsylvania
Conditions: Ependymoma
Register for Updates
Auriculotherapy in the Treatment of Pre-Operative Anxiety
NCT04836936
Recruiting
The goal of this clinical trial is to use the validated PROMIS Emotional Distress - Anxiety - Short Form 8a and PROMIS Emotional Distress-Depression-Short Form pre-and post-intervention to establish a superior correlation between the auriculotherapy treatment and the reduction of perioperative anxiety. Subject population will include those having a partial or total nephrectomy for cancer. Drawing the role that auriculotherapy may play in reducing perioperative anxiety related requirement after s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: UPMC Shadyside Hospital, Pittsburgh, Pennsylvania
Conditions: Anxiety Preoperative
Register for Updates
A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
Recruiting
To evaluate the safety of tolvaptan in pediatric subjects with ARPKD
Gender:
ALL
Ages:
Between 28 days and 18 years
Trial Updated:
08/05/2025
Locations: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania
Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Register for Updates
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130
Recruiting
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
Register for Updates
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
NCT04557956
Recruiting
This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread from where it first started (primary site) to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Register for Updates